Barinthus Biotherapeutics announced clinical data from the Company’s hepatitis B-focused immunotherapeutic candidate, VTP-300, will be highlighted in poster and oral presentations at the European Association for the Study of the Liver, EASL, Congress, taking place June 5-8, 2024, in Milan, Italy. “We are pleased to present the latest data on our immunotherapeutic candidate, VTP-300, at EASL 2024 updated from the data cut we made in January for the abstracts,” said Bill Enright, CEO of Barinthus Bio. “Hepatitis B is considered to be a ‘silent epidemic’ because most people are asymptomatic while infected, allowing the disease to slowly damage the liver. We understand chronic HBV profoundly impacts the quality of life for people living with the disease, and we are excited to share our ongoing research efforts with the overall goal of a working towards a functional cure.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus price target lowered to $11 from $12 at Alliance Global Partners
- Barinthus Biotherapeutics sees cash runway into 4Q25
- Barinthus Biotherapeutics reports Q1 EPS (40c), consensus (54c)
- Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
- Barinthus Biotherapeutics appoints Hooftman as Chief Medical Officer